Abstract
FGF-21 is a potential candidate for the treatment of type 2 diabetes mellitus. However, the clinical application of wild-type human FGF-21 is challenging due to some limitations, such as its poor hypoglycemic potency and short in vivo half-life. In this paper, we have produced an FGF-21 mutant (ahmFGF-21) by exchanging the functional domain of hFGF-21 with that of mFGF-21 to improve the potency of FGF-21. Results showed that the ahmFGF-21 protein was more potent than wild-type hFGF-21 in stimulating glucose uptake in vitro and lowering blood glucose levels of diabetic animals. To decrease its immunogenicity and increase its biostability, the N-terminus of ahmFGF-21 was modified in a sitespecific manner with 20kDa mPEG-propionaldehyde (mPEG-ALD). We found that the preservation time of ahmFGF-21 in vitro was significantly prolonged after PEGylation. The serum antibody levels against ahmFGF-21 in immunized rabbits with the PEGylated ahmFGF-21 were significantly reduced than those with the unmodified ahmFGF-21, and the target protein concentration in the rabbits administrated with the PEGylated ahmFGF-21 increased 9.5-fold higher than that of the unmodified ahmFGF-21. The animal experimental results showed that PEGylation of ahmFGF-21 enhanced the hypoglycemic effect in diabetic mice. These results suggest that the in vitro and in vivo hypoglycemic effects of FGF-21 are significantly enhanced by genetic modification and the metabolic pharmacology of FGF-21 in type 2 diabetic mice is improved by PEGylation at a specific site.
Keywords: Diabetes, FGF-21, genetic modification, immunogenicity, PEGylation, stability.
Current Pharmaceutical Biotechnology
Title:Enhancement of the Pharmacological Efficacy of FGF-21 by Genetic Modification and PEGylation
Volume: 14 Issue: 15
Author(s): Xianlong Ye, Jianying Qi, Guopeng Sun, Guiping Ren, Shenglong Zhu, Yunzhou Wu, Dan Yu, Jingzhuang Zhao, Mingyao Liu and Deshan Li
Affiliation:
Keywords: Diabetes, FGF-21, genetic modification, immunogenicity, PEGylation, stability.
Abstract: FGF-21 is a potential candidate for the treatment of type 2 diabetes mellitus. However, the clinical application of wild-type human FGF-21 is challenging due to some limitations, such as its poor hypoglycemic potency and short in vivo half-life. In this paper, we have produced an FGF-21 mutant (ahmFGF-21) by exchanging the functional domain of hFGF-21 with that of mFGF-21 to improve the potency of FGF-21. Results showed that the ahmFGF-21 protein was more potent than wild-type hFGF-21 in stimulating glucose uptake in vitro and lowering blood glucose levels of diabetic animals. To decrease its immunogenicity and increase its biostability, the N-terminus of ahmFGF-21 was modified in a sitespecific manner with 20kDa mPEG-propionaldehyde (mPEG-ALD). We found that the preservation time of ahmFGF-21 in vitro was significantly prolonged after PEGylation. The serum antibody levels against ahmFGF-21 in immunized rabbits with the PEGylated ahmFGF-21 were significantly reduced than those with the unmodified ahmFGF-21, and the target protein concentration in the rabbits administrated with the PEGylated ahmFGF-21 increased 9.5-fold higher than that of the unmodified ahmFGF-21. The animal experimental results showed that PEGylation of ahmFGF-21 enhanced the hypoglycemic effect in diabetic mice. These results suggest that the in vitro and in vivo hypoglycemic effects of FGF-21 are significantly enhanced by genetic modification and the metabolic pharmacology of FGF-21 in type 2 diabetic mice is improved by PEGylation at a specific site.
Export Options
About this article
Cite this article as:
Ye Xianlong, Qi Jianying, Sun Guopeng, Ren Guiping, Zhu Shenglong, Wu Yunzhou, Yu Dan, Zhao Jingzhuang, Liu Mingyao and Li Deshan, Enhancement of the Pharmacological Efficacy of FGF-21 by Genetic Modification and PEGylation, Current Pharmaceutical Biotechnology 2013; 14 (15) . https://dx.doi.org/10.2174/1389201015666140515124838
DOI https://dx.doi.org/10.2174/1389201015666140515124838 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology Mediterranean Diet and the Metabolic Syndrome: The Role of Protein
Current Nutrition & Food Science Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals Preface: Facing New Challenges in Cardiovascular Disease, When the Pressure Goes Up and the Pump Goes Astray
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Myocardial Revascularization Strategies in Diabetic Patients with Multi-Vessel Disease: CABG vs DES-Based PCI
Current Pharmaceutical Design Model Checking a Synchronous Diabetes-Cancer Logical Network
Current Bioinformatics Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism The Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Current Drug Delivery The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Model for Gestational Diabetes on Web Based Parameters
Recent Patents on Engineering Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Diabetes-induced Alterations in HDL Subfractions Distribution
Current Pharmaceutical Design Formulation Optimization of Human Insulin Loaded Microspheres for Controlled Oral Delivery Using Response Surface Methodology
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews Nontraditional Cardiovascular Risk Factors in Pediatric Type 1 Diabetes
Current Diabetes Reviews